Thank you.
I have a question for Ms. Ermel.
You stated that you would like to see the joint drug review process centralized so that all provinces and territories as well as the federal government adopt a common approach when reviewing the efficacy and cost of drugs.
What process would be the most appropriate to ensure that more drugs, whether it be new oncology drugs or existing drugs, are reviewed and become more widely available to the public, to patients?